company background image

Intravenous InfusionsGHSE:IIL Stock Report

Market Cap







17 Oct, 2021


Company Financials
IIL fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance1/6
Financial Health3/6

IIL Overview

Intravenous Infusions Plc, a pharmaceutical company, manufactures and markets intravenous infusions and small volume injections for therapeutic purposes in Ghana and the West African sub-region.

Price History & Performance

Summary of all time highs, changes and price drops for Intravenous Infusions
Historical stock prices
Current Share PriceGH₵0.05
52 Week HighGH₵0
52 Week LowGH₵0
1 Month Change0%
3 Month Changen/a
1 Year Change0%
3 Year Change-44.44%
5 Year Change-44.44%
Change since IPO-37.50%

Recent News & Updates

Shareholder Returns

IILGH PharmaceuticalsGH Market

Return vs Industry: IIL underperformed the GH Pharmaceuticals industry which returned 87.5% over the past year.

Return vs Market: IIL underperformed the GH Market which returned 67.3% over the past year.

Price Volatility

Is IIL's price volatile compared to industry and market?
IIL volatility
IIL Beta0.48
Industry Beta0.56
Market Beta1

Stable Share Price: Insufficient data to determine IIL's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine IIL's volatility change over the past year.

About the Company

1969n/aSoalihu Moukhtar

Intravenous Infusions Plc, a pharmaceutical company, manufactures and markets intravenous infusions and small volume injections for therapeutic purposes in Ghana and the West African sub-region. The company offers intravenous infusion therapy products, including sodium chloride, dextrose, dextrose saline, poly-saline lactate, and special solutions; pethidine, magnesium sulphate, and quinine small volume injections; administrative sets; and other products, such as metronidazole injection, alcohol rub sanitizers, gel rub, and rubbing/disinfecting. The company was incorporated in 1969 and is based in Koforidua, Ghana.

Intravenous Infusions Fundamentals Summary

How do Intravenous Infusions's earnings and revenue compare to its market cap?
IIL fundamental statistics
Market CapGH₵13.72m
Earnings (TTM)GH₵1.45m
Revenue (TTM)GH₵20.67m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IIL income statement (TTM)
Cost of RevenueGH₵10.49m
Gross ProfitGH₵10.18m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date


Earnings per share (EPS)0.0053
Gross Margin49.27%
Net Profit Margin7.02%
Debt/Equity Ratio66.5%

How did IIL perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Intravenous Infusions undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: IIL (GHS0.05) is trading above our estimate of fair value (GHS0.03)

Significantly Below Fair Value: IIL is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: IIL's PE Ratio (9.5x) is in line with the African Pharmaceuticals industry average.

PE vs Market: IIL is poor value based on its PE Ratio (9.5x) compared to the GH market (5.3x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IIL's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: IIL is good value based on its PB Ratio (0.8x) compared to the XF Pharmaceuticals industry average (1.6x).

Future Growth

How is Intravenous Infusions forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intravenous Infusions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Intravenous Infusions performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IIL has a high level of non-cash earnings.

Growing Profit Margin: IIL's current net profit margins (7%) are lower than last year (8.1%).

Past Earnings Growth Analysis

Earnings Trend: IIL has become profitable over the past 5 years, growing earnings by 30% per year.

Accelerating Growth: IIL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IIL had negative earnings growth (-22.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).

Return on Equity

High ROE: IIL's Return on Equity (8.1%) is considered low.

Financial Health

How is Intravenous Infusions's financial position?

Financial Position Analysis

Short Term Liabilities: IIL's short term assets (GHS23.5M) exceed its short term liabilities (GHS10.9M).

Long Term Liabilities: IIL's short term assets (GHS23.5M) exceed its long term liabilities (GHS8.5M).

Debt to Equity History and Analysis

Debt Level: IIL's debt to equity ratio (66.5%) is considered high.

Reducing Debt: IIL's debt to equity ratio has increased from 26.3% to 66.5% over the past 5 years.

Debt Coverage: IIL's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: IIL's interest payments on its debt are well covered by EBIT (5x coverage).

Balance Sheet


What is Intravenous Infusions's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: IIL's dividend (5.82%) is higher than the bottom 25% of dividend payers in the GH market (4.71%).

High Dividend: IIL's dividend (5.82%) is low compared to the top 25% of dividend payers in the GH market (8.17%).

Stability and Growth of Payments

Stable Dividend: IIL has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: IIL has only been paying a dividend for 2 years, and since then payments have fallen.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (55%), IIL's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Soalihu Moukhtar (50 yo)



Mr. Soalihu M. Moukhtar serves as Managing Director and Director at Intravenous Infusions Plc since September 2020 and served as its Ag. Managing Director since 2020 until 2020. He served as Head of Financ...

Leadership Team

Experienced Management: IIL's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: IIL's board of directors are considered experienced (7.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.

Top Shareholders

Company Information

Intravenous Infusions Plc's employee growth, exchange listings and data sources

Key Information

  • Name: Intravenous Infusions Plc
  • Ticker: IIL
  • Exchange: GHSE
  • Founded: 1969
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: GH₵13.720m
  • Shares outstanding: 274.41m
  • Website:


  • Intravenous Infusions Plc
  • Plot 4/7, Blk L Effiduase
  • PO Box KF 63
  • Koforidua
  • Ghana


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 17:04
End of Day Share Price2021/10/13 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.